UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(XX) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
For the quarterly period ended September 30, 1998
------------------
OR
( ) THE TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.
For the transition period from ______________ to ______________
Commission File Number 01-21617
THE QUIGLEY CORPORATION
-----------------------
(Exact name of registrant as specified in its charter)
Nevada 23-2577138
-----------------------------------------------------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
(MAILING ADDRESS: PO Box 1349, Doylestown, PA 18901.)
Landmark Building, 10 South Clinton Street, Doylestown, PA 18901
----------------------------------------------------------------
(Address of principle executive offices) (Zip Code)
Registrant's telephone number, including area code: (215) 345-0919
------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. [XX] Yes [ ] No
Indicate the number of shares outstanding of each of the issuer's class of
common stock, as of the latest practicable date. The number of shares
outstanding of each of the registrant's classes of common stock, as of October
16, 1998, was 13,142,196 all of one class of $.0005 par value common stock.
<PAGE>
TABLE OF CONTENTS
Page No.
PART I - Financial information
Item 1. Financial Statements 3-9
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations 10-14
Item 3. Quantitative and Qualitative Disclosure About Market Risk 13
PART II - Other Information
Item 1. Legal Proceedings 14
Item 2. Changes in Securities 14
Item 3. Defaults Upon Senior Securities 14
Item 4. Submission of Matters to a Vote of Security Holders 14
Item 5. Other Information 14
Item 6. Exhibits and Reports on Form 8-K 14
Signatures 15
EDGAR Exhibit 27 16
-2-
<PAGE>
THE QUIGLEY CORPORATION
BALANCE SHEETS
ASSETS
September 30, December 31,
1998 1997
(unaudited)
----------- ------------
CURRENT ASSETS:
Cash and cash equivalents $26,690,973 $25,498,359
Accounts receivable, net 8,246,916 10,851,573
Inventory 7,871,752 7,726,757
Prepaid income taxes 4,190,867 3,548,057
Prepaid expenses and other current assets 1,770,231 1,023,628
Deferred income taxes 405,097 591,245
----------- ------------
TOTAL CURRENT ASSETS 49,175,836 49,239,619
----------- ------------
EQUIPMENT - Less accumulated depreciation 331,292 162,189
----------- ------------
OTHER ASSETS:
Patent rights - Less accumulated amortization 307,165 372,986
Other assets 132,749 72,296
----------- ------------
TOTAL OTHER ASSETS 439,914 445,282
----------- -----------
TOTAL ASSETS $49,947,042 $49,847,090
=========== ============
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts Payable $522,890 $1,115,620
Accrued royalties and sales commissions 1,995,995 4,730,856
Accrued freight 253,050 468,577
Other current liabilities 843,689 1,784,019
----------- ------------
TOTAL CURRENT LIABILITIES 3,615,624 8,099,072
----------- ------------
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock, $.01 par value; authorized
1,000,000; no shares issued - -
Common stock, $.0005 par value; authorized
50,000,000; Issued: 14,379,058 and
13,791,358 shares 7,190 6,896
Additional paid-in capital 28,003,992 23,046,551
Retained earnings 24,122,153 19,839,929
Less: Treasury stock, 991,862 and
486,862 shares, at cost (5,801,917) (1,145,358)
----------- ------------
TOTAL STOCKHOLDERS' EQUITY 46,331,418 41,748,018
----------- ------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $49,947,042 $49,847,090
=========== ============
See accompanying notes to financial statements
-3-
<PAGE>
<TABLE>
<CAPTION>
THE QUIGLEY CORPORATION
STATEMENTS OF INCOME
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30, September 30, September 30,
1998 1997 1998 1997
------------- ------------- ------------- -------------
<S> <C> <C> <C> <C>
NET SALES .................... $10,747,978 $14,698,350 $19,337,669 $40,964,092
----------- ----------- ----------- -----------
COST OF SALES ................ 3,175,106 4,322,564 5,784,743 12,436,760
----------- ----------- ----------- -----------
GROSS PROFIT ................. 7,572,872 10,375,786 13,552,926 28,527,332
----------- ----------- ----------- -----------
OPERATING EXPENSES:
Sales and marketing .... 2,052,893 1,635,289 4,971,885 4,556,512
Administration ......... 936,770 1,477,497 2,695,864 4,104,249
----------- ----------- ----------- -----------
TOTAL OPERATING EXPENSES ..... 2,989,663 3,112,786 7,667,749 8,660,761
----------- ----------- ----------- -----------
INCOME FROM OPERATIONS ....... 4,583,209 7,263,000 5,885,177 19,866,571
INTEREST INCOME .............. 357,867 78,218 1,134,863 158,967
----------- ----------- ----------- -----------
INCOME BEFORE TAXES .......... 4,941,076 7,341,218 7,020,040 20,025,538
----------- ----------- ----------- -----------
INCOME TAXES ................. 1,927,020 2,973,193 2,737,816 8,110,343
----------- ----------- ----------- -----------
NET INCOME ................... $ 3,014,056 $ 4,368,025 $ 4,282,224 $11,915,195
=========== =========== =========== ===========
Earnings per common share:
Basic .................. $0.22 $0.36 $0.32 $1.00
=========== =========== =========== ===========
Diluted ................ $0.20 $0.29 $0.28 $0.82
=========== =========== =========== ===========
Weighted average common shares
outstanding:
Basic ................... 13,454,029 12,136,268 13,432,157 11,971,288
=========== =========== =========== ===========
Diluted ................. 14,928,391 14,903,772 15,121,344 14,500,106
=========== =========== =========== ===========
</TABLE>
See accompanying notes to financial statements
-4-
<PAGE>
THE QUIGLEY CORPORATION
STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months Ended
September 30, September 30,
1998 1997
------------- -------------
NET CASH FLOWS FROM OPERATING ACTIVITIES $2,096,522 ($1,289,279)
------------- ------------
CASH FLOWS USED IN INVESTING ACTIVITIES:
Capital expenditures (253,732) (101,702)
Patent rights and other assets (60,453) (44,688)
------------- ------------
NET CASH FLOWS USED IN INVESTING ACTIVITIES (314,185) (146,390)
------------- ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Tax benefits from stock options,
warrants and common stock 3,452,361 5,620,439
Proceeds from exercises of options
and warrants 614,475 368,350
Proceeds from common stock issued - 76,007
Due from attorney's escrow account - 260,000
Change in stock subscription receivable - 355,608
Repurchase of Common stock (4,656,559) -
-------------- ------------
NET CASH FLOWS FROM FINANCING ACTIVITIES (589,723) 6,680,404
-------------- ------------
NET INCREASE IN CASH 1,192,614 5,244,735
CASH & CASH EQUIVALENTS, BEGINNING OF PERIOD 25,498,359 2,455,973
------------- ------------
CASH & CASH EQUIVALENTS, END OF PERIOD $26,690,973 $7,700,708
============= ============
Supplemental disclosure of cash flow information
- ------------------------------------------------
Nine Months Ended
September 30, September 30,
1998 1997
------------- -------------
Non cash investing and financing:
Capital expenditures - ($7,905)
Patent rights - (205,000)
Common stock issued for services performed - 1,358,263
Treasury stock cost - ($1,145,358)
See accompanying notes to financial statements
-5-
<PAGE>
THE QUIGLEY CORPORATION
NOTES TO FINANCIAL STATEMENTS
NOTE 1 - ORGANIZATIONAL AND GENERAL
The Quigley Corporation (the "Company"), organized under the laws of the state
of Nevada, is primarily engaged in the development, manufacturing, and
marketing of homeopathic cold remedies. The products developed are being
offered to the general public through distributors and brokers. For the fiscal
periods presented, and for the immediate future, the Company plans to continue
concentrating its efforts in the promotion of its major proprietary
"Cold-Eeze(R)" products.
These products are based upon a proprietary zinc gluconate glycine formula
which, in two double blind studies have been shown to reduce the severity and
duration of common cold symptoms by nearly half. The results of the latest
randomized double-blind placebo-controlled study of the common cold were
published in 1996 in the Annals of Internal Medicine - Vol. 125 No 2. Research
is continuing on this product in order to maximize its full potential use by
the general public.
The Company has an exclusive agreement for worldwide representation,
manufacturing, marketing and distribution rights for the zinc gluconate
glycine lozenge formulation, known as "Cold-Eeze(R)", which is patented in the
United States, United Kingdom, Sweden, France, Italy, Canada, Germany, and
pending in Japan. In 1996, the Company also acquired exclusive license for a
United States zinc gluconate use patent number RI 33,465 from the patent
holder. This use patent gives the Company exclusive rights to both the use and
formulation patents on zinc gluconate for reducing the duration and severity
of common cold symptoms.
The business of the Company is subject to federal and state laws and
regulations adopted for the health and safety of users of the Company's
products. Cold-Eeze(R) is a homeopathic remedy which is subject to regulations
by various federal, state and local agencies, including the FDA and the
Homeopathic Pharmacopoeia of the United States.
The Company competes with suppliers varying in range and size in the cold
remedy products arena. Cold-Eeze(R) which has been clinically proven, offers a
significant advantage over other suppliers in the over-the-counter cold remedy
market. The management of the Company believes there should be no future
impediment on the ability to compete in the marketplace now, or in the
immediate future, since factors concerning the product, such as, price,
product quality, availability, reliability, credit terms, name recognition,
delivery and support are all properly positioned. The Company has several
Broker, Distributor and Representative Agreements, both nationally and
internationally and the product is distributed through numerous independent
and chain drug and discount stores throughout the United States.
The Company announced in August the addition of a new product relating to
nutrition and weight management. The product is named Bodymate TM and is
expected to be available to the general public early in 1999.
The Cold-Eeze(R) product is produced for the Company by a contract
manufacturer. This manufacturer produces exclusively for the Company.
The Balance Sheet as of September 30, 1998, the Statements of Income for the
three and nine months periods ended September 30, 1998 and 1997, and the
Statements of Cash Flows for the nine month periods ended September 30, 1998
and 1997, have been prepared without audit. In the opinion of management, all
adjustments necessary to present fairly the financial position, results of
operations and cash flows, for the periods indicated, have been made. All
adjustments made were of a normal recurring nature.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting
principles, have been condensed or omitted. It is suggested that these
financial statements be read in conjunction with the financial statements and
accompanying notes for the fiscal year ended December 31, 1997, in the
Company's Form 10-KSB.
-6-
<PAGE>
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
International Licenses
Included in other assets, are amounts that have been capitalized relating to
the Company's development of international licenses. Such amounts are to be
amortized using the straight-line method over the estimated benefit period.
These costs will be expensed should future benefits become impaired.
Reclassifications
Certain prior period amounts have been reclassified to conform with 1998
presentation.
Concentration of Risks
The Company maintains cash and cash equivalents with three major financial
institutions. Since the Company maintains amounts in excess of guarantees
provided by the Federal Depository Insurance Corporation, the Company performs
periodic evaluations of the relative credit standing of these financial
institutions and limits the amount of credit exposure with any one
institution.
The Company currently uses separate suppliers to provide its zinc gluconate
glycine lozenge and the sugarfree line of the product. The lozenge product is
manufactured by a third party manufacturer that produces exclusively for the
Company. The sugarfree line is produced by a manufacturer that produces a
variety of other products for other customers. Should these relationships
terminate or discontinue for any reason, the Company has formulated a
contingency plan necessary in order to prevent such discontinuance from
materially affecting the Company's operations. Any such termination may,
however, result in a temporary delay in production until the replacement
facility is able to meet the Company's production requirements.
Raw material used in the production of the product is available from numerous
sources. Currently, it is being procured from a single vendor in order to
secure purchasing economies. In a situation where this one vendor is not able
to supply the contract manufacturer with the ingredients, other sources have
been identified.
Recently Issued Accounting Standards
In June 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standard ("SFAS") No. 131, "Disclosure about
Segments of an Enterprise and Related Information," requiring that public
companies report certain information about operating segments within their
financial statements. Additionally, it requires that such entities report
certain information about their products and services, the geographic areas in
which they operate, and their major customers. These additional disclosure
requirements are required within financial statements for fiscal years
beginning after December 15, 1997. The Company had international sales in the
second and third quarters of 1998, the resulting revenues are not considered
material. During the remainder of 1998, the Company expects further
international activities that may require additional disclosures in compliance
with the requirements of the Standard.
NOTE 3 - TRANSACTIONS AFFECTING STOCKHOLDERS' EQUITY
On January 8, 1998, the Company's Board of Directors authorized a plan to
reacquire up to 250,000 of the Company's issued and outstanding common stock
shares during the period ended December 31, 1998. On June 24, 1998 the Board
of Directors approved an additional buy-back of up to 500,000 shares of the
Company's Common Stock. The schedule and amount of shares re-purchased will be
based upon market conditions. As of September 30, 1998, 505,000 shares have
been repurchased at an average cost per share of $9.22 giving a total cost of
$4,656,559. From October 1 to October 16, 1998, the Company re-purchased
245,000 shares at an average cost per share of $5.93 giving a total cost of
$1,451,737, fulfilling its previously announced intention to buy-back 750,000
of the Company's shares. On October 15, 1998, the Company's Board of Directors
approved an additional buy-back of up to 2,000,000 shares, which will be based
upon market conditions.
On September 8, 1998, the Company's Board of Directors declared a dividend
distribution of Common Share Purchase Rights ("the Rights"), thereby creating
a Shareholder Rights Plan (the "Plan"). The dividend being payable to the
shareholders of record on September 25, 1998. Each Right entitles the
shareholder of record to purchase from the Company that number of common
shares having a combined market value equal to two times the Rights exercise
price of $45. The Rights are not exercisable until the Distribution Date,
which will be the earlier of a public announcement that a person or group of
affiliated
-7-
<PAGE>
or associated persons has acquired 15% or more of the outstanding Common
Shares, or the announcement of an intention to make a tender or exchange offer
resulting in the ownership of 15% or more of the outstanding Common Shares by
a similarly constituted party. The dividend has the effect of giving the
stockholder a 50% discount on the share's current market value for exercising
such right. In the event of a cashless exercise of the Right, and the acquirer
has acquired less than a 50% beneficial ownership of the Company, a
stockholder may exchange one Right for one common share of the Company. The
Final Expiration of the Plan is September 25, 2008.
On September 8, 1998, the Company's Board of Directors also approved an
amendment to the Company's By-laws to, among other things, increase the
percentage of outstanding shares needed for shareholders to request a special
meeting, the amendments being effective on September 8, 1999. As a result of
this By-law amendment special meetings may be called, for any purpose, by the
chief executive officer, the board of directors or by shareholder(s) holding
25% or more of the voting shares. The amendment further provides that meetings
of the board may be called by the president giving at least 24 hours notice
and also the fiscal year of the Corporation shall be determined by the Board
of Directors. Section 2 of Article XII of the Corporation's By-laws is deleted
in its entirety. The amendment also provides that notice of any meeting of the
Board of Directors may be waived by any director before or after such meeting
either orally or in writing.
During the nine-month period ended September 30, 1998 a total of 587,700
shares were issued through the exercise of stock options and warrants of the
Company resulting in an increase to the additional paid-in-capital of the
Company.
At September 30, 1998, there were 4,380,400 unexercised options and warrants
of the Company's stock.
NOTE 4 - INCOME TAXES
Income taxes include both deferred and currently payable taxes. Deferred
income taxes result from "temporary differences" which consist of a different
tax base for assets and liabilities than their reported amounts in the
financial statements. The deferred tax asset of $405,097 consists of the tax
effects for contract termination costs and miscellaneous items. Certain
exercises of options and warrants during the nine months period ended
September 30, 1998, resulted in reductions to taxes currently payable and a
corresponding increase to additional paid-in-capital totaling $3,452,361.
These reductions are "permanent differences" and do not affect the provisions
for deferred or current income tax expense.
For the nine months ended September 30, 1998 and fiscal year ended December
31, 1997 an effective tax rate has been provided for at 39% and 40.5%
respectively. The reduction in the effective rate was the result of certain
state tax planning strategies employed by the Company during 1998.
NOTE 5 - EARNINGS PER SHARE
Effective December 31, 1997, the Company adopted Statement of Financial
Accounting Standard No. 128, "Earnings Per Share," which simplifies earnings
per share calculations and requires presentation of both basic and diluted
earnings per share on the face of the statement of income. Per this statement,
basic earnings per share ("EPS") excludes dilution and is computed by dividing
income available to common stockholders by the weighted - average number of
common shares outstanding for the period. Diluted EPS reflects the potential
dilution that could occur if securities or other contracts to issue common
stock were exercised or converted into common stock or resulted in the
issuance of common stock that then shared in the earnings of the entity.
Diluted EPS also utilizes the treasury stock method that prescribes a
theoretical buy-back of shares from the theoretical proceeds of all options
and warrants outstanding during the period. Since there is a large number of
options and warrants outstanding, fluctuations in the actual market price can
have a varying of results for each period presented.
A reconciliation of the applicable numerators and denominators of the income
statement periods presented is as follows (millions, except earnings per share
amounts):
<TABLE>
<CAPTION>
Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended
September 30, 1998 September 30, 1997 September 30, 1998 September 30, 1997
Income Shares EPS Income Shares EPS Income Shares EPS Income Shares EPS
------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
Basic EPS ................. $3.0 13.5 $0.22 $4.4 12.1 $0.36 $4.3 13.4 $0.32 $11.9 12.0 $1.00
Dilutives:
Options/Warrants -- 1.4 -- 2.8 -- 1.7 -- 2.5
---- ---- ----- ---- ---- ----- ---- ---- ----- ----- ---- -----
Diluted EPS .... $3.0 14.9 $0.20 $4.4 14.9 $0.29 $4.3 15.1 $0.28 $11.9 14.5 $0.82
==== ==== ===== ==== ==== ===== ==== ==== ===== ===== ==== =====
</TABLE>
-8-
<PAGE>
NOTE 6 - RELATED PARTY TRANSACTIONS
In the ordinary course of business, the Company has sales brokerage
arrangements with entities whose major shareholders are also shareholders of
The Quigley Corporation, or are related to major shareholders of the Company.
Commissions expensed under such arrangements amounted to approximately
$137,000 and $126,000 respectively, for the nine month periods ended
September 30, 1998 and 1997. Management believes these transactions were under
terms no less favorable to the Company than those arranged by other parties.
Amounts payable under such agreements at September 30, 1998 and December 31,
1997 were approximately $8,000 and $58,000 respectively.
The Company is in the process of acquiring licenses in certain countries
through affiliated entities. During 1998, fees have been paid to a related
entity to obtain such licenses amounting to $25,000.
NOTE 7 - STATUS OF NUTRITIONAL FOODS CORPORATION LITIGATION
During 1992, the Company authorized litigation against Nutritional Foods
Corporation ("NFC") in which the Company sought to cancel the 729,928
restricted shares issued to NFC for international marketing services, as a
result of certain false and misleading representations made by it to the
Company including, but not limited to, NFC's failure to act as the Company's
international sales agent under an Agreement between NFC and the Company.
Pursuant to a final decree issued in the Court of Common Pleas of Bucks
County, Pennsylvania dated January 23, 1997, the Company received an order to
return to treasury these outstanding shares. In November of 1997, NFC
challenged the validity of the decree. In March of 1998, a subsequent order of
the Court of Common Pleas of Bucks County modified the decree of January 23,
1997 to provide for a return to treasury of 604,928 shares to the Company. As
payment for legal services, 118,066 of these shares were reissued with a
market value of approximately $1,145,358. This value, the cost of reacquiring
these shares, then became the value of the net treasury stock ($2.35 per
share) represented by 486,862 shares returned to treasury. The impact has been
reflected in the Balance Sheet as of December 31, 1997.
NOTE 8 - COMMITMENTS AND CONTINGENCIES
The Company maintains certain royalty agreements with the founders and
developers, licensors, and consultants for the Cold-Eeze(R) product. The gross
royalty is 13% of sales collected before certain deductions and related tax
benefits. Of this percentage a three percent royalty is payable to the patent
holder whose agreement expires in 2002, a three percent royalty is payable to
the developer of the product formulation together with a two percent
consulting fee based on an agreement that expires in 2007. Additionally, a
founder's commission totaling 5%, on gross receipts on sales of the
Cold-Eeze(R) product less certain deductions, is paid to two of the officers
whose agreements expire in 2005.
The Company has remaining contractual commitments for advertising amounting to
approximately $6,400,000.
The Company has reached an agreement in principle to purchase a building,
including improvements, approximating 14,000 square feet that will be used as
corporate offices as well as laboratory facilities, at a cost approximating
$1.5 million dollars.
In September 1998, the Company increased to $10 million its revolving line of
credit facility with Commerce Bank, N.A. for general corporate purposes. This
facility is collateralized by accounts receivable and inventory and renews in
September 1999, with interest at prime or 275 basis points above the
Euro-Dollar Rate. There were no borrowings under this line during the period
ended September 30, 1998.
The Company is subject to legal proceedings and claims which have arisen in
the ordinary course of its business. Although there can be no assurance as to
the ultimate disposition of these matters, it is the opinion of the Company's
management based upon the information available at this time, that the
expected outcome of these matters, individually or in the aggregate, will not
have a material adverse effect on the financial position, results of
operations or cash flows of the Company.
-9-
<PAGE>
Item 2: Management's Discussion and Analysis of Financial Condition and
Results of Operations
In addition to historical information, this Report contains forward-looking
statements. These forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
reflected in these forward-looking statements. Factors that might cause such a
difference include, but are not limited to management of growth, competition,
pricing pressures on the Company's product, industry growth and general
economic conditions. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect management's opinions only as
of the date hereof. The Company undertakes no obligation to revise or publicly
release the results of any revision to these forward-looking statements. The
Company is subject to a variety of additional risk factors more fully
described in the Company's annual report on Form 10-KSB filed with the
Securities and Exchange Commission.
Overview
- --------
The three and nine month periods ended September 1998 resulted in a
comparative slow down in revenues over the same period in 1997. Revenues for
these three and nine month periods of 1998 were $10,747,978 and $19,337,669 as
compared to $14,698,350 and $40,964,092 for the comparative periods in 1997.
The winter conditions throughout the United States during the 1998 cold season
have been less severe than normal resulting in the reduced sell-through of
Cold-Eeze(R) by our customers. Reflected in the first quarter of 1997, is the
filling of approximately $12 million in backorders at December 31, 1996. The
demand for the product is seasonal, with the fourth and first quarters
representing the largest sales volume.
The Company continues to use the resources of a contract manufacturer and
independent national and international brokers to represent the Company's
Cold-Eeze(R) lozenge product, thereby saving capital and other ongoing
expenditures that would otherwise be incurred.
Manufacturing efficiencies and contract commitments introduced in the first
quarter 1997 resulted in increased product availability, thereby ensuring that
domestic and future international product demand can be met.
During February 1998, an agreement was reached with Genpharm, Inc., a
wholly-owned subsidiary of the pharmaceutical company Merck KgaA, Darmstadt,
Germany, for exclusive distribution of the Company's proprietary Cold-Eeze(R)
products in the Canadian market. In March, the Company reached an agreement
with a Hong Kong based Chinese distribution company for the non-exclusive
distribution of Cold-Eeze(R) in the People's Republic of China. Both
agreements, effective immediately, will launch the international distribution
of the Cold-Eeze(R) product.
During the month of August 1998, the Company made the Cold-Eeze(R) cold remedy
available in a sugarfree tablet form to benefit diabetics and other consumers
concerned with their sugar intake.
The Company announced in August 1998, the addition of a new product relating
to nutrition and weight management. The product is named Bodymate TM and is
expected to be available to the general public early in 1999.
Results of Operations
- ---------------------
Three months ended September 30, 1998 compared to three months ended September
30, 1997
For the three months ended September 30, 1998, the Company reported revenues
of $10,747,978 and net income of $3,014,056 as compared to revenue of
$14,698,350 and net income of $4,368,025 for the comparable period ended
September 30, 1997. The reduction in revenue is due to the mild winter
conditions throughout the United States with the 1998 cold season being less
severe than usual resulting in our customers carrying higher inventory levels
than normal for this time of year.
Cost of Sales as a percentage of net sales for the three months ended
September 30, 1998 was 29.5% compared to 29.4% for the comparable period ended
September 30, 1997. The efficiencies and cost saving processes employed by the
manufacturer in the first quarter of 1997 is continuing. However, offsetting
this gain is the lesser margin being obtained from international sales
together with a change in product configuration.
For the three months ended September 30, 1998, total operating expenses were
$2,989,663 compared to $3,112,786 for the comparable period ended September
30, 1997. The operating expenses have remained high primarily due to a
continuing advertising and promotion campaign commenced during the latter part
of 1997 to establish Cold-Eeze(R) as a recognized brand name and to support
and expand the sales base.
-10-
<PAGE>
During the three months ended September 30, 1998, the major operating expenses
of delivery, salaries, brokerage commissions, promotion, advertising, and
legal costs accounted for $2,701,607 (90%) of total operating costs. The
remaining items for this period remained relatively fixed in that they do not
follow sales trends. These same expense categories for the comparable period
in 1997 accounted for $2,610,462 (84%) of total operating costs. As a
percentage of sales, the 1998 third quarter operating expenses assume a higher
percentage compared to the same period in 1997 due to the lower 1998 sales.
Nine months ended September 30, 1998 compared to nine months ended September
30, 1997
For the nine months ended September 30, 1998, the Company reported revenues of
$19,337,669 and net income of $4,282,224, as compared to revenue of
$40,964,092 and net income of $11,915,195 for the comparable period ended
September 30, 1997. The reduction in revenue is due to the mild winter
conditions throughout the United States with the 1998 cold season being less
severe than usual resulting in our customers carrying higher inventory levels
than normal for this time of year. Also included in the 1997 figure is
approximately $12 million in revenues that represented an order backlog
existing at December 31, 1996.
Cost of Sales as a percentage of net sales for the nine months ended September
30, 1998 was 29.9% compared to 30.4% for the comparable period ended September
30, 1997. This reduction is a result of efficiencies and cost saving processes
employed by the manufacturer which were not in place during the first quarter
of 1997.
For the nine months ended September 30, 1998, total operating expenses, which
include the mitigating effects from changes in accounting estimates, were
$7,667,749 compared to $8,660,761 for the comparable period ended September
30, 1997. The 1998 operating expenses have remained high, despite reduced
sales, primarily due to a continuing advertising and promotion campaign
commenced during the latter part of 1997 to establish Cold-Eeze(R) as a
recognized brand name and to support and expand the sales base. Offsetting
these increased costs is the reduction in brokerage commissions which are a
factor of sales activity.
During the nine months ended September 30, 1998, the major operating expenses
of delivery, salaries, brokerage commissions, promotion, advertising, and
legal costs accounted for $6,716,749 (88%) of total operating costs. The
remaining items for this period remained relatively fixed in that they do not
follow sales trends. These same expense categories for the comparable period
in 1997 accounted for $7,831,126 (90%) of total operating costs.
Liquidity and Capital Resources
- -------------------------------
The total assets of the Company at September 30, 1998 and December 31, 1997
were $49,947,042 and $49,847,090 respectively. Working capital increased to
$45,560,212 from $41,140,547 during the period. The significant movement
within total assets represents the reduction in accounts receivable of
$2,604,657, cash and cash equivalents increasing by $1,192,614, prepaid income
taxes increasing by $642,810, prepaid expenses and other current assets
increasing by $746,603 and inventory increasing by $144,995. From a working
capital perspective, accounts payable, accrued royalties and sales commissions
and other current liabilities were reduced over the period by $592,730,
$2,734,861 and $940,330 respectively. Total cash balances at September 1998
were $26,690,973, as compared to $25,498,359 at December 31, 1997.
The management of the Company currently believes that the current liquidity
and continuing revenues, along with related profits generated, for the
remainder of 1998, should provide an internal source of capital to fund the
Company's business operations. Additionally, in September 1998 the Company
increased its revolving line of credit with Commerce Bank, N.A.to $10 million
to be used for general corporate purposes. This facility is collateralized by
accounts receivable and inventory, and renews in September 1999, with interest
accruing at the Wall Street Journal prime rate, or 275 basis points above the
Euro-Dollar Rate, each to move with the respective base rate. There were no
borrowings under this line during the nine-month period ended September 30,
1998.
On January 8, 1998, the Company's Board of Directors authorized a plan to
reacquire up to 250,000 of the Company's issued and outstanding common stock
shares during the period ended December 31, 1998. On June 24, 1998 the Board
of Directors approved an additional buy-back of up to 500,000 shares of the
Company's Common Stock. The schedule and amount of shares re-purchased are
based upon market conditions. As of September 30, 1998, 505,000 shares have
been repurchased at an average cost per share of $9.22 giving a total cost of
$4,656,559. From October 1 to October 16 the Company has re-purchased 245,000
shares at an average cost per share of $5.93 giving a total cost of
$1,451,737, fulfilling its previously announced intention to buy-back 750,000
of the Company's shares. On October 15, 1998, the Company's Board of Directors
approved an additional buy-back of up to 2,000,000 shares, which will be based
upon market conditions.
-11-
<PAGE>
Management is not aware of any trends, events or uncertainties that have or
are reasonably likely to have a material negative impact upon the Company's
(a) short term or long term liquidity, (b) net sales or revenues or income
from continuing operations. Any challenge to the Company's patent rights could
have a material adverse effect on future liquidity of the Company. However,
the Company is not aware of any condition that would make such an event
probable.
New Accounting Standards
- ------------------------
In June 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standard ("SFAS") No. 131, "Disclosure about
Segments of an Enterprise and Related Information," requiring that public
companies report certain information about operating segments within their
financial statements. Additionally, it requires that such entities report
certain information about their products and services, the geographic areas in
which they operate, and their major customers. These additional disclosure
requirements are required within financial statements for fiscal years
beginning after December 15, 1997. The Company had international sales in the
second and third quarters of 1998, the resulting revenues are not considered
material. During the remainder of 1998, the Company expects further
international activities that may require additional disclosures in compliance
with the requirements of the Standard.
Capital Expenditures
- --------------------
Since the Cold-Eeze(R) lozenge product is manufactured for the Company by an
outside source, capital expenditures during 1998 are not anticipated to be
material. The Company has reached an agreement in principle to purchase a
building, including improvements, approximating 14,000 square feet that will
be used as corporate offices as well as laboratory facilities, at a cost
approximating $1.5 million dollars.
Year 2000 Compliant
- -------------------
The Year 2000 issue relates to the way the computer systems and programs
define calendar dates; they could fail or make miscalculations due to
interpreting a date including "00" to mean 1900, not 2000. Also, many systems
and equipment that are not typically thought of as "computer-related"
(referred to as "non-IT") contain embedded hardware or software that may have
a time element.
The Company began work on the Year 2000 compliance issue in the later part of
1996. The scope of the project includes: ensuring the compliance of all
applications, operating systems and hardware on the Company's computer
network; addressing issues to non-IT embedded software and equipment; and
addressing the compliance of key business partners.
The project has four phases; assessment of the systems and equipment affected
by the Year 2000 issue; definition of strategies to address affected systems
and equipment; remediation of affected systems and equipment; and
certification that each is Year 2000 compliant. To certify that all IT systems
(internally developed, purchased, or licensed) are Year 2000 compliant, each
system is tested using a standard testing methodology which includes
regression testing, millennium testing, millennium leap year testing and cross
over year testing. Certification testing is performed on each system as soon
as remediation is completed.
The most significant category of key business partners is financial
institutions. Their critical functions include safeguarding and management of
investment portfolios, processing of the Company's operating bank accounts,
sales and distribution funds transfers. Other partner categories include
suppliers of communication services, utilities, materials and supplies. Based
on the importance of each relationship, the Company is defining a strategy to
determine compliance.
The target for completion of all phases is the third quarter of 1999. The
Company has completed the assessment and strategy phases for its computer PC
applications, operating systems and hardware.
The majority of the Company's non-IT related systems and equipment are
currently Year 2000 compliant, based primarily on verbal or written
communication with vendors. Compilation of written documentation regarding
compliance is underway and is scheduled to be completed by the third quarter
of 1999. With respect to key business partners, the assessment and strategy
phases are in the preliminary stages, with the Company in the process of
compiling a compliance list. The Company has and continues to conduct surveys
of all its software and hardware vendors, and testing is underway.
-12-
<PAGE>
For business partners with whom the Company engages in electronic transfer of
information, sample testing is and will be conducted until full compliance is
achieved.
The Company has investments in publicly and privately placed securities and
could in the future have loans. The Company may be exposed to credit risk to
the extent that related borrowers are materially adversely impacted by the
Year 2000 issue.
The Company has not had an independent review of its Year 2000 risk or
estimates. However, experts have been engaged to assist in developing
estimates and to complete remediation work on specific portions of the
project.
Since the inception of the project, the Company has not incurred any material
external cost with respect to the Year 2000 issue. Internal cost and current
estimates based on actual experience to date, project a total expense for the
project less than $130,000. The remaining internal cost is not expected to
exceed beyond the cost of normal operating expenses. Current year costs are
expensed as those costs are incurred. There has not been a material adverse
impact on the Company's operations or financial condition as a result of IT
projects caused by the Year 2000 project.
With respect to contingency plans for critical systems, the Company has long
recognized that there is no viable alternative if these systems are
non-compliant. Thus, the Company targeted completion of these systems by year
end 1998, allowing for unanticipated delays. Certification of these systems as
compliant remains on schedule. For non-IT systems and equipment and key
business partners, the Company will continue to reassess the need for formal
contingency plans, based on progress of the Year 2000 efforts by the Company
and third parties.
Although the Company's critical systems are Year 2000 compliant, there is no
guarantee that compliance by third parties whose systems and operation impact
the Company will be completed by the end of 1999. A reasonably possible worst
case scenario might include one or more of the Company's key business partners
being non-compliant. Such an event could result in a material disruption of
the Company's operations. Specifically, the Company could experience an
interruption in its ability to collect and process receipts, broadcast
commercial advertising, safeguard and manage its invested assets and operating
cash accounts, accurately maintain customer information, accurately maintain
accounting records, and/or perform adequate customer service. Should the worst
case scenario occur, it could, depending on its duration, have a material
impact on the Company's results of operations and financial position.
Item 3: Quantitative and Qualitative Disclosure about Market Risk
Not Applicable
-13-
<PAGE>
Part II. Other Information
--------------------------
Item 1. Legal Proceedings
- -------------------------
During 1992, the Company authorized litigation against Nutritional Foods
Corporation ("NFC") in which the Company sought to cancel the 729,928
restricted shares issued to NFC for international marketing services, as a
result of certain false and misleading representations made by it to the
Company including, but not limited to, NFC's failure to act as the Company's
international sales agent under an Agreement between NFC and the Company.
Pursuant to a final decree issued in the Court of Common Pleas of Bucks
County, Pennsylvania dated January 23, 1997, the Company received an order to
return to treasury these outstanding shares. In November of 1997, NFC
challenged the validity of the decree. In March of 1998, a subsequent order of
the Court of Common Pleas of Bucks County modified the decree of January 23,
1997 to provide for a return to treasury of 604,928 shares to the Company. As
payment for legal services, 118,066 of these shares were reissued with a
market value of approximately $1,145,358. This value, the cost of reacquiring
these shares, then became the value of the net treasury stock ($2.35 per
share) represented by 486,862 shares returned to treasury.
The Company is subject to legal proceedings and claims which have arisen in
the ordinary course of its business. Although there can be no assurance as to
the ultimate disposition of these matters, it is the opinion of the Company's
management based upon the information available at this time, that the
expected outcome of these matters, individually or in the aggregate, will not
have a material adverse effect on the financial position, results of
operations or cash flows of the Company.
Item 2. Changes in Securities
- -----------------------------
None
Item 3. Defaults Upon Senior Securities
- ---------------------------------------
None
Item 4. Submission of Matters to a Vote of Security Holders
- -----------------------------------------------------------
None
Item 5. Other Information
- -------------------------
None
Item 6. Exhibits and Reports on Form 8-K
- ----------------------------------------
(a) Exhibits
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K
a) Form 8-K was filed on September 21, 1998 covering the items in Note 3
to the Company's financial statements relating to the Shareholder Rights
Plan.
-14-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
THE QUIGLEY CORPORATION
By: /s/ George J. Longo
-------------------
George J. Longo
Vice President,
Chief Financial Officer
Date: November 2, 1998
<PAGE>
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000868278
<NAME> E.H. Kaytes
<MULTIPLIER> 1
<S> <C> <C>
<CURRENCY> U.S.DOLLARS U.S.DOLLARS
<PERIOD-TYPE> 3-MOS 9-MOS
<FISCAL-YEAR-END> DEC-31-1998 DEC-31-1998
<PERIOD-START> JUL-01-1998 JAN-01-1998
<PERIOD-END> SEP-30-1998 SEP-30-1998
<EXCHANGE-RATE> 1.000 1.000
<CASH> 26,690,973 26,690,973
<SECURITIES> 0 0
<RECEIVABLES> 9,124,752 9,124,752
<ALLOWANCES> 877,836 877,836
<INVENTORY> 7,871,752 7,871,752
<CURRENT-ASSETS> 49,175,836 49,175,836
<PP&E> 470,358 470,358
<DEPRECIATION> 139,066 139,066
<TOTAL-ASSETS> 49,947,042 49,947,042
<CURRENT-LIABILITIES> 3,615,624 3,615,624
<BONDS> 0 0
0 0
0 0
<COMMON> 7,190 7,190
<OTHER-SE> 46,324,228 46,324,228
<TOTAL-LIABILITY-AND-EQUITY> 49,947,042 49,947,042
<SALES> 10,747,978 19,337,669
<TOTAL-REVENUES> 10,747,978 19,337,669
<CGS> 3,175,106 5,784,743
<TOTAL-COSTS> 2,989,663 7,667,749
<OTHER-EXPENSES> 0 0
<LOSS-PROVISION> 0 0
<INTEREST-EXPENSE> 0 0
<INCOME-PRETAX> 4,941,076 7,020,040
<INCOME-TAX> 1,927,020 2,737,816
<INCOME-CONTINUING> 3,014,056 4,282,224
<DISCONTINUED> 0 0
<EXTRAORDINARY> 0 0
<CHANGES> 0 0
<NET-INCOME> 3,014,056 4,282,224
<EPS-PRIMARY> 0.22 0.32
<EPS-DILUTED> 0.20 0.28
</TABLE>
